0000905148-23-000511.txt : 20230726
0000905148-23-000511.hdr.sgml : 20230726
20230726181455
ACCESSION NUMBER: 0000905148-23-000511
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210223
FILED AS OF DATE: 20230726
DATE AS OF CHANGE: 20230726
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: O'Kane Kieran
CENTRAL INDEX KEY: 0001828131
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39659
FILM NUMBER: 231114842
MAIL ADDRESS:
STREET 1: 2970 WILDERNESS PLACE
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIODESIX INC
CENTRAL INDEX KEY: 0001439725
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 203986492
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2970 WILDERNESS PLACE
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: 303-417-0500
MAIL ADDRESS:
STREET 1: 2970 WILDERNESS PLACE
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
form4.xml
X0508
4
2021-02-23
0001439725
BIODESIX INC
BDSX
0001828131
O'Kane Kieran
2970 WILDERNESS PLACE
SUITE 100
BOULDER
CO
80301
true
Chief Commercial Officer
false
Stock Options (Right to buy)
20.67
2021-02-23
4
A
0
25599
0
A
2031-02-22
Common Stock
25599
25599
D
Stock Options (Right to buy)
20.67
2021-02-23
4
A
0
31055
0
A
2031-02-22
Common Stock
31055
31055
D
Stock Options (Right to buy)
20.67
2023-07-24
4
D
0
25599
D
2031-02-22
Common Stock
25599
0
D
Stock Options (Right to buy)
20.67
2023-07-24
4
D
0
31055
D
2031-02-22
Common Stock
31055
0
D
Stock Options (Right to buy)
1.2
2023-07-24
4
A
0
11564
A
2033-07-23
Common Stock
11564
11564
D
This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021.
This option was fully vested as of the grant date.
On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.
The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.
This Replacement Option vests as follows: 8,864 shares of Common Stock underlying this Replacement Option vest on August 1, 2024, and the remaining 2,700 shares of Common Stock underlying this Replacement Option vest in 31 successive, equal monthly installments beginning on August 1, 2024.
/s/ Robin Harper Cowie as Attorney-in-Fact for Kieran O'Kane
2023-07-26